Fortress Biotech Past Earnings Performance
Past criteria checks 0/6
Fortress Biotech has been growing earnings at an average annual rate of 10.9%, while the Biotechs industry saw earnings growing at 29.1% annually. Revenues have been growing at an average rate of 2.5% per year.
Key information
10.91%
Earnings growth rate
27.89%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 2.48% |
| Return on equity | -52.93% |
| Net Margin | -2.97% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
Feb 20Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower
Feb 05
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump
Dec 16Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive
Oct 05Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
Aug 17
FDA Approval Will Open $1 Billion Dermatology Market
Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price
Mar 11Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Oct 29Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Jul 26There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Dec 29There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Aug 18Revenue & Expenses Breakdown
How Fortress Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 63 | -2 | 96 | 0 |
| 30 Sep 25 | 62 | -5 | 105 | 0 |
| 30 Jun 25 | 59 | -24 | 110 | 0 |
| 31 Mar 25 | 58 | -51 | 92 | 0 |
| 31 Dec 24 | 58 | -56 | 88 | 0 |
| 30 Sep 24 | 82 | -58 | 77 | 0 |
| 30 Jun 24 | 83 | -49 | 77 | 0 |
| 31 Mar 24 | 85 | -63 | 80 | 0 |
| 31 Dec 23 | 85 | -69 | 88 | 0 |
| 30 Sep 23 | 62 | -86 | 100 | 0 |
| 30 Jun 23 | 63 | -104 | 108 | 0 |
| 31 Mar 23 | 64 | -100 | 113 | 0 |
| 31 Dec 22 | 76 | -95 | 114 | 0 |
| 30 Sep 22 | 78 | -97 | 113 | 0 |
| 30 Jun 22 | 82 | -93 | 105 | 0 |
| 31 Mar 22 | 81 | -74 | 96 | 0 |
| 31 Dec 21 | 69 | -65 | 87 | 0 |
| 30 Sep 21 | 64 | -38 | 75 | 0 |
| 30 Jun 21 | 53 | -33 | 68 | 0 |
| 31 Mar 21 | 44 | -43 | 63 | 0 |
| 31 Dec 20 | 46 | -47 | 61 | 0 |
| 30 Sep 20 | 43 | -57 | 60 | 24 |
| 30 Jun 20 | 43 | -54 | 59 | 39 |
| 31 Mar 20 | 43 | -54 | 58 | 58 |
| 31 Dec 19 | 37 | -40 | 56 | 81 |
| 30 Sep 19 | 34 | -45 | 56 | 83 |
| 30 Jun 19 | 30 | -51 | 54 | 87 |
| 31 Mar 19 | 27 | -53 | 53 | 86 |
| 31 Dec 18 | 27 | -73 | 53 | 87 |
| 30 Sep 18 | -107 | -61 | 38 | 77 |
| 30 Jun 18 | -65 | -69 | 45 | 73 |
| 31 Mar 18 | -22 | -72 | 48 | 69 |
| 31 Dec 17 | 17 | -65 | 49 | 52 |
| 30 Sep 17 | 155 | -74 | 57 | 49 |
| 30 Jun 17 | 109 | -60 | 47 | 41 |
| 31 Mar 17 | 61 | -55 | 39 | 36 |
| 31 Dec 16 | 16 | -55 | 33 | 35 |
| 30 Sep 16 | 4 | -50 | 32 | 30 |
| 30 Jun 16 | 3 | -55 | 30 | 33 |
| 31 Mar 16 | 1 | -49 | 26 | 29 |
| 31 Dec 15 | 1 | -48 | 22 | 30 |
| 30 Sep 15 | 1 | -40 | 18 | 25 |
| 30 Jun 15 | 1 | -27 | 13 | 16 |
Quality Earnings: FBIO is currently unprofitable.
Growing Profit Margin: FBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 10.9% per year.
Accelerating Growth: Unable to compare FBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.1%).
Return on Equity
High ROE: FBIO has a negative Return on Equity (-52.93%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/27 12:51 |
| End of Day Share Price | 2026/04/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fortress Biotech, Inc. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |